Jared Gollob Sells 4,895 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Jared Gollob sold 4,895 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total value of $417,543.50. Following the transaction, the insider owned 117,134 shares of the company’s stock, valued at approximately $9,991,530.20. This represents a 4.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jared Gollob also recently made the following trade(s):

• On Monday, March 2nd, Jared Gollob sold 5,613 shares of Kymera Therapeutics stock. The shares were sold at an average price of $88.93, for a total value of $499,164.09.
• On Monday, December 8th, Jared Gollob sold 49,307 shares of Kymera Therapeutics stock. The shares were sold at an average price of $88.67, for a total transaction of $4,372,051.69.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $83.52 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The firm has a market capitalization of $6.82 billion, a PE ratio of -22.70 and a beta of 2.20. The company’s 50 day simple moving average is $78.75 and its 200 day simple moving average is $66.52.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same period in the prior year, the firm posted ($0.88) EPS. The firm’s quarterly revenue was down 60.8% on a year-over-year basis. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Analyst Upgrades and Downgrades

Several research firms have issued reports on KYMR. Oppenheimer upped their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Stephens boosted their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday. UBS Group upped their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday. B. Riley Financial lifted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Kymera Therapeutics by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after buying an additional 1,833 shares during the period. Millennium Management LLC grew its stake in Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Kymera Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after purchasing an additional 59,347 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.